# Integra Lifesciences Holdings (IART) — Earnings

IART · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/iart/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.56 |
| EPS estimate | $0.48 |
| EPS surprise | +16.55% |
| Revenue surprise | +0.29% |
| Revenue | $418.8M |
| Revenue estimate | $417.5M |
| Reported | Jul 29, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/917520/000091752026000058/iart-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/e714bf96-c2f0-360d-36d2-ba09a451acbe.html) |

Integra LifeSciences reported Q2 2026 results on July 29, 2026. EPS of $0.56 beat the $0.48 estimate by 16.55%. Revenue was $418.8 million, slightly above the $417.5 million consensus. Compared with Q2 2025, EPS rose about 24% from $0.45, while revenue was nearly flat, up 0.8% from $415.6 million.

The table shows earnings drifting lower for several years before a recent pickup. Annual EPS fell from $3.36 in 2022 to $3.10 in 2023, $2.56 in 2024 and $2.23 in 2025, even as yearly revenue grew from $1.56 billion to $1.64 billion. The first half of 2026 adds up to $1.10 per share, about 28% above the $0.86 of a year earlier. Q4 is the strongest quarter of each year, and Q4 2024 holds the highs here at $0.97 per share and $442.6 million in revenue. Integra beat the EPS estimate in 15 of the last 20 quarters and in each of the last five.

Q3 results came between October 25 and November 4 in each of the past five years, which points to late October or early November 2026 for the next report. It will show whether the year-over-year EPS gains of 2026 carry into the third quarter.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 29, 2026 | $0.48 | $0.56 | 16.55% | $417.5M | $418.8M |
| Q1 2026 | May 5, 2026 | $0.40 | $0.54 | 33.37% | $381.8M | $391.9M |
| Q4 2025 | Feb 26, 2026 | $0.80 | $0.83 | 3.72% | $429.6M | $434.9M |
| Q3 2025 | Oct 30, 2025 | $0.43 | $0.54 | 24.37% | $414.2M | $402.1M |
| Q2 2025 | Jul 31, 2025 | $0.44 | $0.45 | 3.16% | $395.0M | $415.6M |
| Q1 2025 | May 5, 2025 | $0.43 | $0.41 | -4.89% | $381.2M | $382.7M |
| Q4 2024 | Feb 25, 2025 | $0.85 | $0.97 | 13.58% | $445.1M | $442.6M |
| Q3 2024 | Nov 4, 2024 | $0.39 | $0.41 | 5.10% | $375.8M | $380.8M |
| Q2 2024 | Jul 29, 2024 | $0.62 | $0.63 | 1.04% | $413.1M | $418.2M |
| Q1 2024 | May 6, 2024 | $0.55 | $0.55 | -0.36% | $363.7M | $368.9M |
| Q4 2023 | Feb 28, 2024 | $0.90 | $0.89 | -1.44% | $399.3M | $397.0M |
| Q3 2023 | Oct 25, 2023 | $0.78 | $0.76 | -2.36% | $387.2M | $382.4M |
| Q2 2023 | Jul 27, 2023 | $0.57 | $0.71 | 24.71% | $374.0M | $381.3M |
| Q1 2023 | Apr 26, 2023 | $0.74 | $0.74 | 0.33% | $373.2M | $380.8M |
| Q4 2022 | Feb 22, 2023 | $0.90 | $0.94 | 4.03% | $397.9M | $398.0M |
| Q3 2022 | Oct 26, 2022 | $0.72 | $0.86 | 19.39% | $378.3M | $385.2M |
| Q2 2022 | Jul 27, 2022 | $0.80 | $0.82 | 2.59% | $395.3M | $397.8M |
| Q1 2022 | Apr 27, 2022 | $0.68 | $0.74 | 8.30% | $362.4M | $376.6M |
| Q4 2021 | Feb 23, 2022 | $0.84 | $0.84 | -0.10% | $404.6M | $405.5M |
| Q3 2021 | Nov 2, 2021 | $0.72 | $0.86 | 18.72% | $384.6M | $386.9M |

## Frequently Asked Questions

### When did Integra Lifesciences Holdings (IART) last report earnings?

Integra Lifesciences Holdings last reported on Jul 29, 2026, covering fiscal Q2 2026.

### Did IART beat earnings estimates?

Yes. Integra Lifesciences Holdings reported EPS of $0.56 for Q2 2026 against a $0.48 estimate — a 16.55% beat.

### How much revenue did IART report last quarter?

Integra Lifesciences Holdings reported $418.8M in revenue for Q2 2026, against a consensus estimate of $417.5M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).